Medicenna Therapeutics Corp. Share Price

Equities

MDNA

CA58490H1073

Biotechnology & Medical Research

Delayed Toronto S.E. 16:24:52 30/05/2024 BST 5-day change 1st Jan Change
2.36 CAD +3.96% Intraday chart for Medicenna Therapeutics Corp. +0.85% +461.90%

Financials

Sales 2024 * - Sales 2025 * 500K 366K 28.72M Capitalization 170M 124M 9.75B
Net income 2024 * -15M -10.98M -861M Net income 2025 * -19M -13.9M -1.09B EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 339 x
P/E ratio 2024 *
-10.3 x
P/E ratio 2025 *
-9.08 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.81%
More Fundamentals * Assessed data
Dynamic Chart
Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum MT
Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee MT
Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting MT
Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P. CI
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding CI
Medicenna Therapeutics Up 13% After Flagging Presentations MT
Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024 MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting CI
More news
1 day+3.96%
1 week+0.85%
Current month+1.72%
1 month+1.72%
3 months+100.00%
6 months+381.63%
Current year+461.90%
More quotes
1 week
2.22
Extreme 2.22
2.44
1 month
2.22
Extreme 2.22
2.89
Current year
0.40
Extreme 0.4
2.89
1 year
0.22
Extreme 0.215
2.89
3 years
0.22
Extreme 0.215
4.84
5 years
0.22
Extreme 0.215
7.25
10 years
0.22
Extreme 0.215
7.25
More quotes
Managers TitleAgeSince
Founder - 30/09/11
Chief Executive Officer - 01/02/15
Director of Finance/CFO - 02-13
Members of the board TitleAgeSince
Director/Board Member 72 23/09/19
Director/Board Member - 21/11/16
Chief Executive Officer - 01/02/15
More insiders
Date Price Change Volume
30/05/24 2.36 +3.96% 34 600
29/05/24 2.27 -1.30% 78,425
28/05/24 2.3 -5.74% 43,298
27/05/24 2.44 +3.39% 28,726
24/05/24 2.36 +0.85% 50,104

Delayed Quote Toronto S.E., May 30, 2024 at 04:24 pm

More quotes
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.27 CAD
Average target price
5.2 CAD
Spread / Average Target
+129.07%
Consensus